Haloperidol IM Dosage Recommendations
For adults with acute agitation, use haloperidol IM 2-5 mg initially, with repeat doses every 4-8 hours as needed; for elderly or debilitated patients, start with lower doses (0.5-1 mg); and for children aged 5-12 years, use 0.5-2 mg IM, while adolescents (13+ years) can receive 2-5 mg IM. 1
Adult Dosing
The FDA-approved dosing for haloperidol IM provides clear guidance 1:
- Standard adult dose: 2-5 mg IM for prompt control of acute agitation in schizophrenia with moderately severe to very severe symptoms
- Repeat dosing: Can be administered as frequently as every hour if needed, though 4-8 hour intervals are typically satisfactory
- Transition to oral: Switch to oral formulation as soon as practicable, using the previous 24-hour parenteral dose as an initial approximation for total daily oral dose
Important Considerations for Adults
Haloperidol remains the conventional antipsychotic with the strongest evidence base for treating agitation 2. However, recent comparative data shows that while effective, it has a slower onset than alternatives—median time to sedation of 23 minutes compared to 8.5 minutes for midazolam 3. Additionally, haloperidol carries risks of extrapyramidal symptoms and cardiovascular effects including dystonia and potential cardiac arrest 3.
Elderly and Debilitated Patients
For geriatric or debilitated patients, use significantly lower doses with more gradual titration 1:
- Initial dose: 0.5-1 mg IM (or even ≤0.5 mg)
- Rationale: Recent evidence strongly supports low-dose haloperidol in older adults
The evidence for low-dose haloperidol in elderly patients is compelling. A 2025 propensity-matched study found that doses ≤0.5 mg were at least as safe and effective as higher doses (>0.5 mg), with patients receiving higher doses actually more likely to require alternative sedatives 4. A 2023 study demonstrated that low-dose haloperidol (≤0.5 mg) resulted in no patients requiring additional doses within 4 hours, compared to patients in medium and high-dose groups, and was associated with shorter length of stay and less restraint use 5. A 2013 retrospective review found that higher than recommended doses provided no evidence of increased effectiveness but did result in significantly greater risk of sedation 6.
Critical Pitfall in Elderly Patients
Despite guideline recommendations, 37.5% of elderly patients receive initial doses exceeding 1 mg 6. This represents overdosing that increases adverse events without improving efficacy. Always start with 0.5 mg or less in patients ≥65 years old.
Pediatric Dosing (Ages 5 and Older)
Based on pediatric emergency medicine guidelines 7:
Children (Ages 6-12 years, prepubertal)
- Initial dose: 0.5-2 mg IM
- Alternative calculation: 0.1 mg/kg IM
- Repeat dosing: May repeat every 20-30 minutes for tranquilization
Adolescents (Ages 13+ years)
- Younger adolescents (12-16 years): 2-5 mg IM
- Older adolescents (>16 years): 5-10 mg IM
- Maximum daily dose: 40 mg
- Repeat dosing: May repeat every 20-30 minutes; alternatively every 2 hours
Pediatric Combination Therapy
The guidelines suggest combination approaches for adolescents 7:
- Haloperidol + lorazepam or midazolam (for older adolescents >16 years)
- Haloperidol + diphenhydramine (to reduce extrapyramidal symptoms)
Pediatric Monitoring Considerations
Critical adverse effects requiring close monitoring include 7:
- Dystonic reactions (more common in young males and with higher doses)
- Orthostatic hypotension
- Cardiac dysrhythmias
- Extrapyramidal symptoms
Important caveat: Controlled trials establishing safety and effectiveness of IM haloperidol in children have not been conducted 1. The pediatric dosing recommendations come from clinical practice guidelines rather than FDA approval for this age group.
Special Populations
Hepatic or Renal Impairment
The FDA label recommends individualized dosing with careful monitoring but does not provide specific dose reductions 1. In practice, start at the lower end of the dosing range (2 mg for adults, 0.5 mg for elderly) and titrate cautiously.
Clinical Context and Alternatives
While haloperidol has the most robust evidence base among conventional antipsychotics 2, newer evidence suggests atypical antipsychotics may be preferable. Ziprasidone 20 mg IM showed superior efficacy to haloperidol with better tolerability and notably absent movement disorders 2, 8. A 2021 trial found midazolam and olanzapine preferable to haloperidol due to faster sedation and fewer cardiovascular/extrapyramidal risks 3.
The key advantage of haloperidol remains its extensive evidence base and familiarity to clinicians, but this must be weighed against slower onset and higher risk of movement disorders compared to alternatives.